Which has higher valuation & earnings, FRMM or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than Forum Markets. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forum Markets $6.55M 13.90 -$450.52M -$36.07 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is FRMM or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% NLS Pharmaceutics N/A N/A N/A

Does the media refer more to FRMM or NCEL?

In the previous week, Forum Markets had 6 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 10 mentions for Forum Markets and 4 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.72 beat Forum Markets' score of 0.62 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ATRA or NCEL?

Atara Biotherapeutics has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atara Biotherapeutics $120.77M 0.60 $32.69M -$0.67 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Which has higher earnings & valuation, CRDF or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than Cardiff Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiff Oncology $590K 151.80 -$45.85M -$0.67 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Does the media refer more to CRDF or NCEL?

In the previous week, NLS Pharmaceutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat NLS Pharmaceutics' score of 0.72 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, NCEL or RANI?

NLS Pharmaceutics has higher earnings, but lower revenue than Rani Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Rani Therapeutics $1.63M 49.32 -$29.67M -$0.41 N/A

Is NCEL or RANI more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Rani Therapeutics N/A -206.46% -83.95%

Does the media prefer NCEL or RANI?

In the previous week, Rani Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 4 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.72 beat Rani Therapeutics' score of 0.69 indicating that NLS Pharmaceutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, NCEL or BTMD?

biote has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A biote $192.22M 0.43 $27.05M $0.44 4.98

Does the media prefer NCEL or BTMD?

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 4 articles in the media. biote's average media sentiment score of 1.37 beat NLS Pharmaceutics' score of 0.72 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NLS Pharmaceutics (NCEL) Competitors

$3.98 -0.02 (-0.50%)

As of 04:00 PM Eastern

Compare

NCEL vs. FRMM, ATRA, CRDF, RANI, and BTMD

Should you buy NLS Pharmaceutics stock or one of its competitors? MarketBeat compares NLS Pharmaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NLS Pharmaceutics include Forum Markets (FRMM), Atara Biotherapeutics (ATRA), Cardiff Oncology (CRDF), Rani Therapeutics (RANI), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does NLS Pharmaceutics compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Forum Markets had 6 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 10 mentions for Forum Markets and 4 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.72 beat Forum Markets' score of 0.62 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forum Markets has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Forum Markets presently has a consensus price target of $10.00, suggesting a potential upside of 47.06%. NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 477.89%. Given NLS Pharmaceutics' higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics' return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
NLS Pharmaceutics	N/A	N/A	N/A

4.1% of Forum Markets shares are owned by institutional investors. 25.2% of Forum Markets shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NLS Pharmaceutics has lower revenue, but higher earnings than Forum Markets.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	13.90	-$450.52M	-$36.07	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Summary

Forum Markets beats NLS Pharmaceutics on 7 of the 12 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, NLS Pharmaceutics had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.94 beat NLS Pharmaceutics' score of 0.72 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
NLS Pharmaceutics	Positive

Atara Biotherapeutics has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.60	$32.69M	-$0.67	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Atara Biotherapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 18.16%. NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 477.89%. Given NLS Pharmaceutics' higher probable upside, analysts plainly believe NLS Pharmaceutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atara Biotherapeutics has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

70.9% of Atara Biotherapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NLS Pharmaceutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. NLS Pharmaceutics' return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
NLS Pharmaceutics	N/A	N/A	N/A

Summary

NLS Pharmaceutics beats Atara Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

NLS Pharmaceutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. NLS Pharmaceutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
NLS Pharmaceutics	N/A	N/A	N/A

Cardiff Oncology has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

16.3% of Cardiff Oncology shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NLS Pharmaceutics has lower revenue, but higher earnings than Cardiff Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	151.80	-$45.85M	-$0.67	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, NLS Pharmaceutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat NLS Pharmaceutics' score of 0.72 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiff Oncology presently has a consensus target price of $7.50, indicating a potential upside of 472.52%. NLS Pharmaceutics has a consensus target price of $23.00, indicating a potential upside of 477.89%. Given NLS Pharmaceutics' higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NLS Pharmaceutics beats Cardiff Oncology on 7 of the 13 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Rani Therapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

NLS Pharmaceutics currently has a consensus target price of $23.00, suggesting a potential upside of 477.89%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 1,248.23%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Rani Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 4 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.72 beat Rani Therapeutics' score of 0.69 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NLS Pharmaceutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Rani Therapeutics	N/A	-206.46%	-83.95%

30.2% of Rani Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NLS Pharmaceutics has higher earnings, but lower revenue than Rani Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Rani Therapeutics	$1.63M	49.32	-$29.67M	-$0.41	N/A

NLS Pharmaceutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

Rani Therapeutics beats NLS Pharmaceutics on 7 of the 12 factors compared between the two stocks.

How does NLS Pharmaceutics compare to biote?

NLS Pharmaceutics (NASDAQ:NCEL) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

biote has a net margin of 8.29% compared to NLS Pharmaceutics' net margin of 0.00%. NLS Pharmaceutics' return on equity of 0.00% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
biote	8.29%	-25.72%	15.12%

biote has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
biote	$192.22M	0.43	$27.05M	$0.44	4.98

NLS Pharmaceutics presently has a consensus target price of $23.00, indicating a potential upside of 477.89%. biote has a consensus target price of $2.75, indicating a potential upside of 25.57%. Given NLS Pharmaceutics' higher possible upside, research analysts plainly believe NLS Pharmaceutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

21.7% of biote shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 4 articles in the media. biote's average media sentiment score of 1.37 beat NLS Pharmaceutics' score of 0.72 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
biote	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NLS Pharmaceutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, biote has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Summary

biote beats NLS Pharmaceutics on 10 of the 12 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCEL vs. The Competition

Export

Metric	NLS Pharmaceutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.38M	$3.02B	$6.85B	$12.45B
Dividend Yield	N/A	2.08%	2.68%	8.43%
P/E Ratio	N/A	18.77	27.04	24.38
Price / Sales	N/A	344.35	524.25	93.51
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	2.50	4.20	10.80	6.33
Net Income	-$8.30M	$65.13M	$3.59B	$331.02M
7 Day Performance	-0.75%	-3.41%	-2.24%	-1.09%
1 Month Performance	23.22%	2.41%	3.12%	-0.49%
1 Year Performance	-81.31%	20.10%	26.30%	19.90%

NLS Pharmaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCEL NLS Pharmaceutics	3.6067 of 5 stars	$3.98 -0.5%	$23.00 +477.9%	-81.0%	$21.38M	N/A	N/A	6	Positive News Analyst Forecast Gap Up
FRMM Forum Markets	3.3281 of 5 stars	$6.11 +7.1%	$10.00 +63.8%	N/A	$88.79M	$9.41M	N/A	7	News Coverage Analyst Revision
ATRA Atara Biotherapeutics	2.6738 of 5 stars	$9.78 -4.7%	$9.50 -2.9%	-6.1%	$88.12M	$23.14M	N/A	330
CRDF Cardiff Oncology	3.7584 of 5 stars	$1.28 -5.6%	$7.50 +488.2%	-66.8%	$87.04M	$590K	N/A	20	Gap Down
RANI Rani Therapeutics	1.9247 of 5 stars	$0.69 -2.7%	$8.75 +1,168.1%	-1.8%	$85.23M	$1.63M	N/A	110	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. FRMM, ATRA, CRDF, RANI, and BTMD

How does NLS Pharmaceutics compare to Forum Markets?

Summary

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

Summary

How does NLS Pharmaceutics compare to Cardiff Oncology?

Summary

How does NLS Pharmaceutics compare to Rani Therapeutics?

Summary

How does NLS Pharmaceutics compare to biote?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. FRMM, ATRA, CRDF, RANI, and BTMD

How does NLS Pharmaceutics compare to Forum Markets?

Does the media refer more to FRMM or NCEL?

Which has more risk & volatility, FRMM or NCEL?

Do analysts prefer FRMM or NCEL?

Is FRMM or NCEL more profitable?

Do institutionals and insiders have more ownership in FRMM or NCEL?

Which has higher valuation & earnings, FRMM or NCEL?

Summary

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

Does the media refer more to ATRA or NCEL?

Which has higher earnings & valuation, ATRA or NCEL?

Do analysts rate ATRA or NCEL?

Which has more risk & volatility, ATRA or NCEL?

Do insiders and institutionals have more ownership in ATRA or NCEL?

Is ATRA or NCEL more profitable?

Summary

How does NLS Pharmaceutics compare to Cardiff Oncology?

Is CRDF or NCEL more profitable?

Which has more risk and volatility, CRDF or NCEL?

Do institutionals & insiders believe in CRDF or NCEL?

Which has higher earnings & valuation, CRDF or NCEL?

Does the media refer more to CRDF or NCEL?

Do analysts rate CRDF or NCEL?

Summary

How does NLS Pharmaceutics compare to Rani Therapeutics?

Do analysts prefer NCEL or RANI?

Does the media prefer NCEL or RANI?

Is NCEL or RANI more profitable?

Do insiders and institutionals hold more shares of NCEL or RANI?

Which has stronger earnings and valuation, NCEL or RANI?

Which has more risk and volatility, NCEL or RANI?

Summary

How does NLS Pharmaceutics compare to biote?

Is NCEL or BTMD more profitable?

Which has stronger earnings and valuation, NCEL or BTMD?

Do analysts rate NCEL or BTMD?

Do institutionals & insiders believe in NCEL or BTMD?

Does the media prefer NCEL or BTMD?

Which has more volatility & risk, NCEL or BTMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools